I-Mab will present two new results of lezolimab at the 2022 American Society of Hematology (ASH) Annual Meeting

I-Mab (the "Company") (NASDAQ: IMAB) is a clinical-stage biopharmaceutical company focused on target biology research, antibody processes, clinical development and commercialization of products in the U.
S
.
, providing novel and effective therapies for urgently needed cancer treatments worldwide 。 The company announced on November 3 that it will announce its latest translational research data
for its innovative CD47 antibody letzorolimab in the form of a poster during the 64th Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans, USA, December 10-13, 2022.

Dr.
Xiuxuan Zhu, President and Acting Chief Executive Officer of I-Mab, said, "The company is rapidly advancing the clinical development of dezonolimab and exploring its clinical application potential and innovative drug combination solutions
.
At this year's ASH conference, we will share the results of biomarker data analysis of the phase 2 clinical trial of letzolumab in combination with azacitidine for myelodysplastic syndrome, as well as the data from the combination of letzolimab and fizetumab targeting CD38 in the treatment of high-risk multiple myeloma
.
These research results will provide a solid theoretical basis
for us to formulate clinical development strategies faster and more accurately.
”

       ：Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of

       Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic

       Syndrome (HR-MDS)

Abstract ID: 3974

Speaker: Professor Chang Chunkang, Shanghai Sixth People's Hospital

Presentation: 604.
Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Location: Ernest N.
Morial Convention Center, Hall D

Date/Time: December 12, 2022, 6:00-8:00 PM EDT

Abstract Overview: The combination therapy of lezorolimab and azacitidine can induce upregulation of calreticin expression in tumor cells, and the number of macrophages and CD8/Treg ratio in the bone marrow at baseline are positively correlated with clinical efficacy, suggesting that the activation of tumor pro-swallowing signals and the number of effector cells play an important role
in the effect of combination therapy.
In addition, we observed better efficacy in patients with TP53 mutations compared to TP53 wild-type patients, who expressed higher calreticulin levels in bone marrow and had a higher proportion of immune cell infiltration
.
The results of this study reveal the mechanism
of action of the combination of lezorolimab and azacitidine in the treatment of HR-MDS indications at the level of tumor cells and immune cells.

       ：Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in

       Relapsed or Refractory Multiple Myeloma

Abstract ID: 4462

Presented by: I-Mab, Dr.
Yanni Zhang

Presentation: 651.
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Location: Ernest N.
Morial Convention Center, Hall D

Date/Time: December 12, 2022, 6:00-8:00 PM EDT

Summary Overview: Through this study, we found that in patients with relapsed and refractory multiple myeloma, tumor cells with high expression of CD47 and low expression of CD38 were positively correlated with poor prognosis of the disease, and this phenomenon occurred in a higher
proportion of patients with high-risk multiple myeloma.
The data showed that high-risk multiple myeloma cells were not sensitive to CD38 antibody monotherapy such as daratumumab or fizetumab, and the combination therapy of lezolimab and fizetumab could effectively enhance the antibody-dependent phagocytic activity and in vivo antitumor effect
of such myeloma cells.
This result provides preclinical data to
explore the combination of lezolibab and fizetumab in patients with high-risk multiple myeloma.

Detailed research data will be shared
in the on-site report of the conference.
The company will launch two complete posters on the company's official website after the ASH annual meeting on December 13, so stay tuned
.

About CD47 and lezorolimab

CD47 is a glycoprotein widely expressed on the surface of a variety of cancer cells, which releases the "don't eat me" signal by connecting with SIRPα on the surface of tumor phagocytes to prevent macrophage phagocytosis
.
CD47 antibody can block this signal and make macrophages attack tumor cells, so it has become one of
the most promising tumor immune targets.
However, while CD47 antibodies attack tumor cells, they will bind to normal red blood cells and cause hematological side effects, such as severe anemia, which hinders
the development and clinical application of CD47 antibodies as cancer treatment.
I-Mab scientists have discovered a unique CD47 antibody, letzorolizumab, that effectively targets tumor cells while minimizing adverse effects on red blood cells to avoid severe anemia
.

At present, a number of clinical studies of lezolibab in combination with chemotherapy or immune checkpoint inhibitors for the treatment of hematological tumors (including acute myeloid leukemia/myelodysplastic syndrome) and solid tumors are being carried out in China and the United States, and the relevant research results will promote letzorolimab to quickly enter the registration clinical trial stage
in China.

About fizetumab

Fizetumab (also known as TJ202/MOR202) is a human monoclonal antibody
exclusively developed by MorphoSys in Germany using HuCAL® technology.
The CD38 antigen on the surface of multiple myeloma targeted by this antibody belongs to the most strongly expressed and uniform tumor antigen on the surface of malignant plasma cells
.
The mechanism of action of this antibody is to kill CD38-expressing tumor cells
through antibody-dependent cytotoxicity and antibody-dependent cell phagocytosis.
However, complement-dependent cytotoxicity (CDC)
is not involved.
Studies have shown that CD38 antibodies also have therapeutic potential
in other cancers and autoimmune diseases.
I-Mab has exclusive rights
to develop and commercialize pheneturtumab in Chinese mainland, Taiwan, Hong Kong and Macau under a license agreement signed between I-Mab and MorphoSys in November 2017.

HuCAL® is a registered trademark
of MorphoSys Corporation.